Squarepoint Ops LLC Reduces Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Squarepoint Ops LLC decreased its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 55.9% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 50,756 shares of the company’s stock after selling 64,349 shares during the period. Squarepoint Ops LLC owned 0.07% of Zentalis Pharmaceuticals worth $154,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. State of Wyoming lifted its holdings in Zentalis Pharmaceuticals by 124.6% during the 4th quarter. State of Wyoming now owns 34,716 shares of the company’s stock worth $105,000 after purchasing an additional 19,262 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at about $52,000. Nuveen Asset Management LLC raised its holdings in shares of Zentalis Pharmaceuticals by 35.2% in the 4th quarter. Nuveen Asset Management LLC now owns 641,407 shares of the company’s stock valued at $1,943,000 after acquiring an additional 167,062 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Zentalis Pharmaceuticals by 8.1% in the 4th quarter. Millennium Management LLC now owns 957,563 shares of the company’s stock valued at $2,901,000 after acquiring an additional 71,477 shares in the last quarter. Finally, Integral Health Asset Management LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at about $3,182,000.

Insider Activity

In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers acquired 21,000 shares of the company’s stock in a transaction on Wednesday, April 30th. The stock was acquired at an average price of $1.40 per share, for a total transaction of $29,400.00. Following the acquisition, the director now owns 281,192 shares in the company, valued at $393,668.80. This represents a 8.07% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 1.90% of the company’s stock.

Zentalis Pharmaceuticals Trading Up 3.4%

Shares of Zentalis Pharmaceuticals stock opened at $1.52 on Monday. The firm has a market capitalization of $109.37 million, a PE ratio of -0.61 and a beta of 1.61. The business’s 50-day moving average price is $1.29 and its 200-day moving average price is $2.08. Zentalis Pharmaceuticals, Inc. has a 12 month low of $1.01 and a 12 month high of $10.68.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, meeting the consensus estimate of ($0.67). As a group, analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ZNTL. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Wedbush reaffirmed a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $8.24.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.